

In the specification:

At p. 11, line 10, before the sentence starting "Other dimers ..." please insert the following 3 paragraphs:

D: Single disulfide-bonded dimer as in Figure 1A except the Fc domain is linked at the N-terminus of the peptide X<sup>1</sup>.

E. Doubly disulfide-linked dimers as in Figure 1B except the Fc domain is linked at the N-terminus of peptide X<sup>1</sup>.

F. Noncovalent dimers as in Figure 1C except the Fc domain is linked at the N-terminus of peptide X<sup>1</sup>.

At p. 12, please replace the paragraph at line 17, with the following:

Figure 7 shows cAMP accumulation in ROS 17/2.8 rat osteoblast-like cells. Cultures were treated with the phosphodiesterase inhibitor IBMX and then challenged for 15 minutes with various PTH fragments. cAMP was measured by ELISA.

--cAMP levels are shown for the following cultures:

(-IBMX), without phosphodiesterase inhibitor;

(Inc. B + Veh.), with vehicle (PBS);

(1-34)10<sup>-10</sup>, treated with IBMX and challenged with PTH[1-34] at a concentration of 10<sup>-10</sup> M;

(1-34)10<sup>-8</sup>, treated with IBMX and challenged with PTH[1-34] at a concentration of 10<sup>-8</sup> M;

(1-34)10<sup>-6</sup>, treated with IBMX and challenged with PTH[1-34] at a concentration of 10<sup>-6</sup> M;

(1-31)Fc10<sup>-10</sup>, treated with IBMX and challenged with PTH[1-31]-Fc at a concentration of 10<sup>-10</sup> M;

(1-31)Fc10<sup>-8</sup>, treated with IBMX and challenged with PTH[1-31]-Fc at a concentration of 10<sup>-8</sup> M;

(1-31)Fc10<sup>-6</sup>, treated with IBMX and challenged with PTH[1-31]-Fc at a concentration of 10<sup>-6</sup> M;

(1-30)Fc10<sup>-10</sup>, treated with IBMX and challenged with PTH[1-30]-Fc at a concentration of 10<sup>-10</sup> M;

(1-30)Fc10<sup>-8</sup>, treated with IBMX and challenged with PTH[1-30]-Fc at a concentration of 10<sup>-8</sup> M;

(1-30)Fc10<sup>-6</sup>, treated with IBMX and challenged with PTH[1-30]-Fc at a concentration of 10<sup>-6</sup> M.--

At p. 13, please replace the paragraph at line 3 with the following:

Figure 10 shows the effect of twice-weekly PTH-(1-34)-Fc versus daily PTH-(1-34) on tibial, trabecular, and cortical bone mineral density (BMD) panels A, B, and C, respectively. Daily PTH [PTH-(1-34)] was given at 80 µg/kg/day (20 nmol/kg/day).

At p. 13, please replace the paragraph at line 6 with the following:

Figure 11 shows the effects of twice-weekly treatment on BMD and serum calcium in aged ovariectomized (OVX) rats. Eleven months after OVX, rats were treated twice per week with phosphate-buffered saline (PBS,

vehicle) or with APD (0.5 mg/kg) or with PTH-(1-34)-Fc (50 nmol/kg). DEXA was performed weekly. Blood was drawn 24 hours after the second weekly injection, when the calcemic effects of PTH-Fc are typically maximal. The effects of PTH-Fc administration on lumbar BMD (Figure 11A), tibia/femur BMD (Figure 11B), femoral metaphysis BMD (Figure 11C), and serum calcium (Figure 11D) were determined.